ecancermedicalscience

Research

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma

13 Jan 2021
Gunjesh Kumar Singh, Hollis DSouza, Nandini Menon, Sujay Srinivas, Dilip Harindran Vallathol, Mounika Boppana, Annu Rajpurohit, Abhishek Mahajan, Amit Janu, Abhishek Chatterjee, Rahul Krishnatry, Tejpal Gupta, Rakesh Jalali, Vijay M Patil

Background: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma patients between the biosimilar and innovator molecules.

Materials and methods: Adult recurrent/progressive glioblastoma patients treated with bevacizumab from 1 July 2015 to 30 July 2019 were identified. These patients were either offered Bevacizumab innovator (Avastin, Roche) or biosimilar (BevaciRel: Reliance Life sciences or Bryxta: Zydus Oncosciences) depending upon the financial status and affordability of the patients. The primary endpoint of the study was OS, while progression-free survival (PFS) and adverse events were the secondary endpoints.

Results: There were 82 patients, out of which 57 received innovator and 25 received biosimilar bevacizumab. At median follow-up of 26 months, the median PFS was 3.66 (95% confidence interval (CI) 2.08 to 5.25) and 3.3 months (95% CI 2.38 to 4.21) in innovator and biosimilar group, respectively (Log-rank test p-value = 0.072). The hazard ratio (HR) for progression was 0.61 (95% CI 0.35 to 1.05; p-value = 0.075). At the time of data cut-off, the median OS was 5.53 (95% CI, 5.07 to 5.99) versus 7.33 months (95% CI, 5.63 to 9.03) in innovator and biosimilar group, respectively (Log-rank test p-value = 0.51). The HR for death was 1.21 (95% CI, 0.67 to 2.17; p-value = 0.51). The adverse events and safety profiles were comparable between the two groups.

Conclusion: In the recurrent/progressive glioblastoma patients, both innovator and biosimilar bevacizumab seem to have similar safety and clinical efficacy.

Article metrics: 136 views
136

Related Articles

Milena Perez Mak, Fatima Solange Pasini, Lixia Diao, Fabyane O Teixeira Garcia, Tiago Kenji Takahashi, Denyei Nakazoto, Renata Eiras Martins, Cristiane Maria Almeida, Marco Aurelio Vamondes Kulcsar, Valdelania Aparecida Lamounier, Emily Montosa Nunes, Isabela Cristina de Souza, Marcio Ricardo Taveira Garcia, Alex Vieira Amadio, Sheila Aparecida C Siqueira, Igor Moysés Longo Snitcovsky, Laura Sichero, Jing Wang, Gilberto de Castro Jr
Maria Asunción Algarra, Maria José Juan Fita, Sergio Sandiego, Héctor Augusto Aguilar, Pablo Álvarez, Mateo Quispe, Antonio Salvador, Adoración Egido, Javier Lavernia, Isidro Machado, José Rubio Briones, Miguel Ángel Climent
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco
Lotfi Kochbati, Verna Vanderpuye, Rim Moujahed, Mouna Ben Rejeb, Zeineb Naimi, Tajudeen Olasinde